title: Systemic Therapies for Nonmetastatic Breast Cancer: The Role of Neoadjuvant and Adjuvant Chemotherapy and the Use of Endocrine Therapy.
abstract: Breast cancer is a heterogenous disease, comprised of at least 3 major subtypes: hormone receptor-positive/HER2-(HR+), HER2+, and HR-/HER2-(triple negative) breast cancers. The medical management of each subype is distinct. In this article, we review contemporary data supporting the use of chemotherapy, endocrine therapy and biologic therapies, especially HER2-directed agents, in the adjuvant and neoadjuvant setting in patients with newly diagnosed nonmetastatic (stage I-III) breast cancer.
authors.affiliation: *Dana-Farber Cancer Institute †Harvard Medical School ‡Massachusetts General Hospital Cancer Center, Boston, Massachusetts §Program in Women's Oncology, Women and Infants Hospital of Rhode Island, Alpert Medical School of Brown University, Providence, Rhode Island.
authors.forename: Brittany L
authors.initials: BL
authors.lastname: Bychkovsky
authors.forename: Don S
authors.initials: DS
authors.lastname: Dizon
authors.forename: William M
authors.initials: WM
authors.lastname: Sikov
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001691:Biological Therapy / Q000379:methods; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000235:genetics; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D018734:Genes, erbB-2; D006801:Humans; D020360:Neoadjuvant Therapy / Q000379:methods*; D016032:Randomized Controlled Trials as Topic; D011960:Receptors, Estrogen / Q000627:therapeutic use*; D011980:Receptors, Progesterone / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone